Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study

Abstract Background: Adding daratumumab to initial therapy in randomized controlled trials (RCTs) for newly diagnosed multiple myeloma (MM) enhances deep remission and prolongs progression-free survival (PFS). Given the differences between trial-eligible and real-world patients, and healthcare acces...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yun Wang, Xiaoqin Chen, Qi Liang, Weida Wang, Jun Luo, Lin Luo, Ru Feng, Yongqiang Wei, Yuyang Tian, Xin Du, Zhenqian Huang, Guoyu Hu, Xiangjun Fu, Shi Tao, Jihao Zhou, Hongling Peng, Yongzhong Su, Hongyu Zhang, Min Dong, Mei Lan, Zhiqiang Sun, Xiuju Wang, Hui Zhou, Liye Zhong, Rober Peter Gale, Yang Liang, Zhongjun Xia
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Springer 2026-02-01
coleção:	Annals of Hematology
Assuntos:	Daratumumab Multiple myeloma First-line therapy Survival Minimal residual disease
Acesso em linha:	https://doi.org/10.1007/s00277-026-06808-5
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!